丙种球蛋白无反应及敏感川崎病患儿血小板、干扰素-γ和白介素-6表达水平及其临床意义

Expression levels of PLT, IFN-γ and IL-6 in gammaglobulin non-responsive or sensitive children with Kawasaki disease and their clinical significance

  • 摘要: 目的:探讨丙种球蛋白无反应及敏感川崎病患儿血小板(PLT)、干扰素-γ(IFN-γ)、白介素-6(IL-6)表达水平的差异及临床意义。方法:选取2019年5月至2022年6月厦门大学附属中山医院收治的99例川崎病患儿,根据丙种球蛋白治疗反应性分为无反应组24例和敏感组75例,比较两组基线水平及12 h、36 h PLT、IFN-γ、IL-6表达水平。采用Logistic回归分析川崎病丙种球蛋白无反应的相关影响因素,采用受试者工作特征曲线(ROC)分析PLT、IFN-γ、IL-6及联合预测川崎病丙种球蛋白无反应的价值,采用DeLong检验不同方案的预测价值,采用临床决策曲线分析法(DCA)分析PLT+IFN-γ+IL-6方案预测川崎病丙种球蛋白反应性的临床效用。结果:无反应组12 h及36 h PLT、IFN-γ、IL-6表达水平与基线水平比较,差异无统计学意义(P> 0.05);敏感组12 h及36 h PLT、IFN-γ、IL-6表达水平均低于基线水平(P< 0.05);无反应组基线水平及12 h、36 h PLT、IFN-γ、IL-6表达水平高于敏感组(P< 0.05);基线PLT、IFN-γ、IL-6均为川崎病丙种球蛋白无反应的独立相关影响因素(P< 0.05);PLT、IFN-γ、IL-6及联合的ROC曲线下面积(AUC)依次为0.818、0.767、0.712、0.915,PLT+IFN-γ+IL-6的AUC高于IFN-γ、IL-6(P< 0.05),与PLT比较,差异无统计学意义(P> 0.05);采用PLT+IFN-γ+IL-6方案预测川崎病丙种球蛋白无反应具有临床正向的净获益。结论:川崎病丙种球蛋白无反应和敏感患儿PLT、IFN-γ、IL-6表达水平存在显著差异,与患儿治疗反应性有关,联合检测PLT、IFN-γ、IL-6可预测丙种球蛋白治疗反应。

     

    Abstract: Objective:To investigate the differences and clinical significance of platelet (PLT), interferon-gamma(IFN-γ), and interleukin-6(IL-6)expression levels between gammaglobulin non-responsive and sensitive children with Kawasaki disease.Methods:Ninety-nine Kawasaki disease patients admitted to Zhongshan Hospital Xiamen University from May 2019 to June 2022 were selected and divided into non-responsive group(24 cases)and sensitive group(75 cases)according to the response of gammaglobulin treatment.Baseline levels and the expression levels of PLT, IFN-γ and IL-6 at 12 h and 36 h were compared between the two groups.Logistic regression was used to analyze the influencing factors related to gammaglobulin non-response in Kawasaki disease, receiver operating characteristic curve(ROC)was used to analyze the value of PLT, IFN-γ, IL-6 and combined prediction of gammaglobulin non-response in Kawasaki disease, and DeLong was used to test the predictive value of different regimens.Clinical decision curve analysis(DCA)was used to analyze the clinical utility of PLT+IFN-γ+IL-6 regimen to predict gammaglobulin reactivity in Kawasaki disease.Results:The expression levels of PLT, IFN-γ and IL-6 at 12 h and 36 h in the non-responsive group were not statistically significant compared with baseline level (P> 0.05); the expression levels of PLT, IFN-γ and IL-6 in sensitive group at 12 h and 36 h were lower than baseline levels (P< 0.05); baseline level and expression levels of PLT, IFN-γ and IL-6 at12 h and 36 h in non-responsive group were higher than those in sensitive group(P< 0.05); baseline PLT, IFN-γ and IL-6 were all independent relevant influencing factors for non-response to Kawasaki disease gammaglobulin(P< 0.05); the area under the ROC curve (AUC) of PLT, IFN-γ, IL-6 and combination was 0.818, 0.767, 0.712 and 0.915, respectively, the AUC of PLT+IFN-γ+IL-6 was higher than that of IFN-γ and IL-6(P< 0.05), but the difference with PLT was not statistically significant (P> 0.05); there was a net positive clinical benefit of using the PLT+IFN-γ+IL-6 regimen to predict gammaglobulin non-response in Kawasaki disease.Conclusion:There are significant differences in the expression levels of PLT, IFN-γ and IL-6 in children with Kawasaki disease who do not respond to gammaglobulin and those who are sensitive to gammaglobulin, which is related to the therapeutic reactivity of the children.Combined detection of PLT, IFN-γ and IL-6 can predict the therapeutic response of gammaglobulin.

     

/

返回文章
返回